Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bryan L Roth

Showing results (261-270 of 450) with videos related to

Pageof 45
Sort By:
Psychopharmacology|April 2, 2010
Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in ratsChristina L Nemeth, Tracie A Paine, Joseph E Rittiner, et al.
Journal of Medicinal Chemistry|March 25, 2017
Structure-Based Discovery of New Antagonist and Biased Agonist Chemotypes for the Kappa Opioid ReceptorZhong Zheng, Xi-Ping Huang, Thomas J Mangano, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2006
p90 ribosomal S6 kinase 2 exerts a tonic brake on G protein-coupled receptor signalingDouglas J Sheffler, Wesley K Kroeze, Bonnie G Garcia, et al.
ACS Chemical Biology|March 15, 2013
Conformation guides molecular efficacy in docking screens of activated β-2 adrenergic G protein coupled receptorDahlia R Weiss, SeungKirl Ahn, Maria F Sassano, et al.
Cell Reports|September 10, 2013
DREADDs in Drosophila: a pharmacogenetic approach for controlling behavior, neuronal signaling, and physiology in the flyJaime Becnel, Oralee Johnson, Zana R Majeed, et al.
Science Translational Medicine|May 8, 2024
MRGPRX4 mediates phospho-drug-associated pruritus in a humanized mouse modelDaphne Chun-Che Chien, Nathachit Limjunyawong, Can Cao, et al.
Journal of Medicinal Chemistry|October 23, 2013
4β-Methyl-5-(3-hydroxyphenyl)morphan opioid agonist and partial agonist derived from a 4β-methyl-5-(3-hydroxyphenyl)morphan pure antagonistF Ivy Carroll, Moses G Gichinga, John D Williams, et al.
Farmaco (Societa Chimica Italiana : 1989)|September 19, 2003
Synthesis and in vitro pharmacology of novel heterocyclic muscarinic ligandsMarco De Amici, Paola Conti, Ezio Fasoli, et al.
Molecular Pharmacology|July 17, 2008
New insights into the function of M4 muscarinic acetylcholine receptors gained using a novel allosteric modulator and a DREADD (designer receptor exclusively activated by a designer drug)Vindhya Nawaratne, Katie Leach, Nur Suratman, et al.
The Journal of Biological Chemistry|October 15, 2013
Chemotype-selective modes of action of κ-opioid receptor agonistsEyal Vardy, Philip D Mosier, Kevin J Frankowski, et al.
Pageof 45

Showing results (261-270 of 450) with videos related to

Sort By:
Pageof 45
Psychopharmacology|April 2, 2010
Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in ratsChristina L Nemeth, Tracie A Paine, Joseph E Rittiner, et al.
Journal of Medicinal Chemistry|March 25, 2017
Structure-Based Discovery of New Antagonist and Biased Agonist Chemotypes for the Kappa Opioid ReceptorZhong Zheng, Xi-Ping Huang, Thomas J Mangano, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2006
p90 ribosomal S6 kinase 2 exerts a tonic brake on G protein-coupled receptor signalingDouglas J Sheffler, Wesley K Kroeze, Bonnie G Garcia, et al.
ACS Chemical Biology|March 15, 2013
Conformation guides molecular efficacy in docking screens of activated β-2 adrenergic G protein coupled receptorDahlia R Weiss, SeungKirl Ahn, Maria F Sassano, et al.
Cell Reports|September 10, 2013
DREADDs in Drosophila: a pharmacogenetic approach for controlling behavior, neuronal signaling, and physiology in the flyJaime Becnel, Oralee Johnson, Zana R Majeed, et al.
Science Translational Medicine|May 8, 2024
MRGPRX4 mediates phospho-drug-associated pruritus in a humanized mouse modelDaphne Chun-Che Chien, Nathachit Limjunyawong, Can Cao, et al.
Journal of Medicinal Chemistry|October 23, 2013
4β-Methyl-5-(3-hydroxyphenyl)morphan opioid agonist and partial agonist derived from a 4β-methyl-5-(3-hydroxyphenyl)morphan pure antagonistF Ivy Carroll, Moses G Gichinga, John D Williams, et al.
Farmaco (Societa Chimica Italiana : 1989)|September 19, 2003
Synthesis and in vitro pharmacology of novel heterocyclic muscarinic ligandsMarco De Amici, Paola Conti, Ezio Fasoli, et al.
Molecular Pharmacology|July 17, 2008
New insights into the function of M4 muscarinic acetylcholine receptors gained using a novel allosteric modulator and a DREADD (designer receptor exclusively activated by a designer drug)Vindhya Nawaratne, Katie Leach, Nur Suratman, et al.
The Journal of Biological Chemistry|October 15, 2013
Chemotype-selective modes of action of κ-opioid receptor agonistsEyal Vardy, Philip D Mosier, Kevin J Frankowski, et al.
Pageof 45